1
|
San Martin G, Hautier L, Mingeot D, Dubois B. How reliable is metabarcoding for pollen identification? An evaluation of different taxonomic assignment strategies by cross-validation. PeerJ 2024; 12:e16567. [PMID: 38313030 PMCID: PMC10838070 DOI: 10.7717/peerj.16567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Accepted: 11/12/2023] [Indexed: 02/06/2024] Open
Abstract
Metabarcoding is a powerful tool, increasingly used in many disciplines of environmental sciences. However, to assign a taxon to a DNA sequence, bioinformaticians need to choose between different strategies or parameter values and these choices sometimes seem rather arbitrary. In this work, we present a case study on ITS2 and rbcL databases used to identify pollen collected by bees in Belgium. We blasted a random sample of sequences from the reference database against the remainder of the database using different strategies and compared the known taxonomy with the predicted one. This in silico cross-validation (CV) approach proved to be an easy yet powerful way to (1) assess the relative accuracy of taxonomic predictions, (2) define rules to discard dubious taxonomic assignments and (3) provide a more objective basis to choose the best strategy. We obtained the best results with the best blast hit (best bit score) rather than by selecting the majority taxon from the top 10 hits. The predictions were further improved by favouring the most frequent taxon among those with tied best bit scores. We obtained better results with databases containing the full sequences available on NCBI rather than restricting the sequences to the region amplified by the primers chosen in our study. Leaked CV showed that when the true sequence is present in the database, blast might still struggle to match the right taxon at the species level, particularly with rbcL. Classical 10-fold CV-where the true sequence is removed from the database-offers a different yet more realistic view of the true error rates. Taxonomic predictions with this approach worked well up to the genus level, particularly for ITS2 (5-7% of errors). Using a database containing only the local flora of Belgium did not improve the predictions up to the genus level for local species and made them worse for foreign species. At the species level, using a database containing exclusively local species improved the predictions for local species by ∼12% but the error rate remained rather high: 25% for ITS2 and 42% for rbcL. Foreign species performed worse even when using a world database (59-79% of errors). We used classification trees and GLMs to model the % of errors vs. identity and consensus scores and determine appropriate thresholds below which the taxonomic assignment should be discarded. This resulted in a significant reduction in prediction errors, but at the cost of a much higher proportion of unassigned sequences. Despite this stringent filtering, at least 1/5 sequences deemed suitable for species-level identification ultimately proved to be misidentified. An examination of the variability in prediction accuracy between plant families showed that rbcL outperformed ITS2 for only two of the 27 families examined, and that the % correct species-level assignments were much better for some families (e.g. 95% for Sapindaceae) than for others (e.g. 35% for Salicaceae).
Collapse
Affiliation(s)
- Gilles San Martin
- Life Sciences Department, Plant and Forest Health Unit, Walloon Agricultural Research Centre, Gembloux, Belgium
| | - Louis Hautier
- Life Sciences Department, Plant and Forest Health Unit, Walloon Agricultural Research Centre, Gembloux, Belgium
| | - Dominique Mingeot
- Life Sciences Department, Bioengineering Unit, Walloon Agricultural Research Centre, Gembloux, Belgium
| | - Benjamin Dubois
- Life Sciences Department, Bioengineering Unit, Walloon Agricultural Research Centre, Gembloux, Belgium
| |
Collapse
|
2
|
Dickson SP, Haaland B, Mallinckrodt CH, Dubois B, O'Keefe P, Morgan M, Peters O, Fernández Santana Iii A, Harrison J, Schneeberger A, Hendrix S. "Time Saved" Calculations to Improve Decision-Making in Progressive Disease Studies. J Prev Alzheimers Dis 2024; 11:529-536. [PMID: 38706269 PMCID: PMC11060991 DOI: 10.14283/jpad.2024.64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2023] [Accepted: 02/11/2024] [Indexed: 05/07/2024]
Abstract
BACKGROUND Disease modifying therapies (DMTs) may be most beneficial in early disease, when progression is slow and changes small, with clinical relevance difficult to interpret. OBJECTIVES Time component tests (TCTs) translate differences between treatments from mean change, vertical distance between longitudinal trajectories, into intuitively understood time saved, horizontal distance between trajectories, which can be readily combined across endpoints in a global TCT (gTCT). DESIGN The value of composites, time savings estimates, and combination scores to optimize measurement and interpretation of DMTs are demonstrated, along with construction details and simulation studies. SETTING TCT methods were applied to a randomized phase II clinical trial. PARTICIPANTS Patients with early Alzheimer's disease (N=332). INTERVENTION Three treatment groups with AFFITOPE® AD02 and two control groups with aluminum oxyhydroxide, AD04. MEASUREMENTS The co-primary efficacy outcomes were an adapted ADAS-Cog (aADAS) and adapted ADCS-ADL (aADL), which were optimized composite scales specific to cognitive and functional domains. A composite based on these two scores was the study's prespecified primary outcome. The CDR-sb and standard non-adapted ADCS-ADL and ADAS-Cog scales were prespecified secondary outcomes. RESULTS The AD04 2 mg group showed some statistically significant effects compared with other study arms. It is unclear whether the observed 3.8-point difference on the composite is clinically meaningful. TCT results show a time savings of 11 months in an 18-month study with AD04 2 mg. CONCLUSION The relevance of 11 months saved is more universally understood than a mean difference of 3.8 points in the composite outcome. These results suggest that a combination of a composite approach and a time savings interpretation offers a powerful approach for detecting and interpreting disease modifying effects.
Collapse
Affiliation(s)
- S P Dickson
- Achim Schneeberger, Advantage Therapeutics, 195 NW 40th St, Miami, FL 33127 United States, , +43 69911098989
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Liu H, Li J, Ziegemeier E, Adams S, McDade E, Clifford DB, Cao Y, Wang G, Li Y, Mills SL, Santacruz AM, Belyew S, Grill JD, Snider BJ, Mummery CJ, Surti G, Hannequin D, Wallon D, Berman SB, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sanchez-Valle R, Brooks WS, Gauthier S, Galasko D, Masters CL, Brosch J, Hsiung GYR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Bateman RJ, Llibre-Guerra JJ. Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials. J Prev Alzheimers Dis 2024; 11:558-566. [PMID: 38706272 DOI: 10.14283/jpad.2024.61] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/07/2024]
Abstract
BACKGROUND Clinical trial satisfaction is increasingly important for future trial designs and is associated with treatment adherence and willingness to enroll in future research studies or to recommend trial participation. In this post-trial survey, we examined participant satisfaction and attitudes toward future clinical trials in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU). METHODS We developed an anonymous, participant satisfaction survey tailored to participants enrolled in the DIAN-TU-001 double-blind clinical trial of solanezumab or gantenerumab and requested that all study sites share the survey with their trial participants. A total of 194 participants enrolled in the trial at 24 study sites. We utilized regression analysis to explore the link between participants' clinical trial experiences, their satisfaction, and their willingness to participate in upcoming trials. RESULTS Survey responses were received over a sixteen-month window during 2020-2021 from 58 participants representing 15 study sites. Notably, 96.5% of the survey respondents expressed high levels of satisfaction with the trial, 91.4% would recommend trial participation, and 96.5% were willing to enroll again. Age, gender, and education did not influence satisfaction levels. Participants reported enhanced medical care (70.7%) and pride in contributing to the DIAN-TU trial (84.5%). Satisfaction with personnel and procedures was high (98.3%). Respondents had a mean age of 48.7 years, with most being from North America and Western Europe, matching the trial's demographic distribution. Participants' decisions to learn their genetic status increased during the trial, and most participants endorsed considering future trial participation regardless of the DIAN-TU-001 trial outcome. CONCLUSION Results suggest that DIAN-TU-001 participants who responded to the survey exhibited high motivation to participate in research, overall satisfaction with the clinical trial, and willingness to participate in research in the future, despite a long trial duration of 4-7 years with detailed annual clinical, cognitive, PET, MRI, and lumbar puncture assessments. Implementation of features that alleviate barriers and challenges to trial participation is like to have a high impact on trial satisfaction and reduce participant burden.
Collapse
Affiliation(s)
- H Liu
- Jorge J Llibre Guerra, 4488 Forest Park 00328, T: 314.273-5439, St. Louis MO 63108, USA, ; Haiyan Liu, 4488 Forest Park 00328, T: 314.273-5819, St. Louis MO 63108, USA,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Dubois B, Debode F, Hautier L, Hulin J, Martin GS, Delvaux A, Janssen E, Mingeot D. A detailed workflow to develop QIIME2-formatted reference databases for taxonomic analysis of DNA metabarcoding data. BMC Genom Data 2022; 23:53. [PMID: 35804326 PMCID: PMC9264521 DOI: 10.1186/s12863-022-01067-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 07/01/2022] [Indexed: 11/10/2022] Open
Abstract
Background The DNA metabarcoding approach has become one of the most used techniques to study the taxa composition of various sample types. To deal with the high amount of data generated by the high-throughput sequencing process, a bioinformatics workflow is required and the QIIME2 platform has emerged as one of the most reliable and commonly used. However, only some pre-formatted reference databases dedicated to a few barcode sequences are available to assign taxonomy. If users want to develop a new custom reference database, several bottlenecks still need to be addressed and a detailed procedure explaining how to develop and format such a database is currently missing. In consequence, this work is aimed at presenting a detailed workflow explaining from start to finish how to develop such a curated reference database for any barcode sequence. Results We developed DB4Q2, a detailed workflow that allowed development of plant reference databases dedicated to ITS2 and rbcL, two commonly used barcode sequences in plant metabarcoding studies. This workflow addresses several of the main bottlenecks connected with the development of a curated reference database. The detailed and commented structure of DB4Q2 offers the possibility of developing reference databases even without extensive bioinformatics skills, and avoids ‘black box’ systems that are sometimes encountered. Some filtering steps have been included to discard presumably fungal and misidentified sequences. The flexible character of DB4Q2 allows several key sequence processing steps to be included or not, and downloading issues can be avoided. Benchmarking the databases developed using DB4Q2 revealed that they performed well compared to previously published reference datasets. Conclusion This study presents DB4Q2, a detailed procedure to develop custom reference databases in order to carry out taxonomic analyses with QIIME2, but also with other bioinformatics platforms if desired. This work also provides ready-to-use plant ITS2 and rbcL databases for which the prediction accuracy has been assessed and compared to that of other published databases. Supplementary Information The online version contains supplementary material available at 10.1186/s12863-022-01067-5.
Collapse
|
5
|
Cappelle S, Pareto D, Sunaert S, Smets I, Laenen A, Dubois B, Demaerel P. T1w/FLAIR ratio standardization as a myelin marker in MS patients. Neuroimage Clin 2022; 36:103248. [PMID: 36451354 PMCID: PMC9668645 DOI: 10.1016/j.nicl.2022.103248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 10/20/2022] [Accepted: 10/23/2022] [Indexed: 11/06/2022]
Abstract
INTRODUCTION Calculation of a T1w/T2w ratio was introduced as a proxy for myelin integrity in the brain of multiple sclerosis (MS) patients. Since nowadays 3D FLAIR is commonly used for lesion detection instead of T2w images, we introduce a T1w/FLAIR ratio as an alternative for the T1w/T2w ratio. OBJECTIVES Bias and intensity variation are widely present between different scanners, between subjects and within subjects over time in T1w, T2w and FLAIR images. We present a standardized method for calculating a histogram calibrated T1w/FLAIR ratio to reduce bias and intensity variation in MR sequences from different scanners and at different time-points. MATERIAL AND METHODS 207 Relapsing Remitting MS patients were scanned on 4 different 3 T scanners with a protocol including 3D T1w, 2D T2w and 3D FLAIR images. After bias correction, T1w/FLAIR ratio maps and T1w/T2w ratio maps were calculated in 4 different ways: without calibration, with linear histogram calibration as described by Ganzetti et al. (2014), and by using 2 methods of non-linear histogram calibration. The first nonlinear calibration uses a template of extra-cerebral tissue and cerebrospinal fluid (CSF) brought from Montreal Neurological Institute (MNI) space to subject space; for the second nonlinear method we used an extra-cerebral tissue and CSF template of our own subjects. Additionally, we segmented several brain structures such as Normal Appearing White Matter (NAWM), Normal Appearing Grey Matter (NAGM), corpus callosum, thalami and MS lesions using Freesurfer and Samseg. RESULTS The coefficient of variation of T1w/FLAIR ratio in NAWM for the no calibrated, linear, and 2 nonlinear calibration methods were respectively 24, 19.1, 9.5, 13.8. The nonlinear methods of calibration showed the best results for calculating the T1w/FLAIR ratio with a smaller dispersion of the data and a smaller overlap of T1w/FLAIR ratio in the different segmented brain structures. T1w/T2w and T1w/FLAIR ratios showed a wider range of values compared to MTR values. CONCLUSIONS Calibration of T1w/T2w and T1w/FLAIR ratio maps is imperative to account for the sources of variation described above. The nonlinear calibration methods showed the best reduction of between-subject and within-subject variability. The T1w/T2w and T1w/FLAIR ratio seem to be more sensitive to smaller changes in tissue integrity than MTR. Future work is needed to determine the exact substrate of T1w/FLAIR ratio and to obtain correlations with clinical outcome.
Collapse
Affiliation(s)
- S. Cappelle
- Department of Radiology, University Hospitals Leuven, Leuven, Belgium,Corresponding author
| | - D. Pareto
- Department of Radiology (IDI), Vall d’Hebron University Hospital, Barcelona, Spain
| | - S. Sunaert
- Department of Radiology, University Hospitals Leuven, Leuven, Belgium,Department of Imaging & Pathology, Translational MRI, KU Leuven, Leuven, Belgium
| | - I. Smets
- Laboratory for Neuroimmunology, KU Leuven, Leuven, Belgium,Department of Neurology, Erasmus MC, Rotterdam, The Netherlands
| | - A. Laenen
- Interuniversity Institute for Biostatistics and Statistical Bioinformatics, KU Leuven and Hasselt University, Leuven, Belgium
| | - B. Dubois
- Laboratory for Neuroimmunology, KU Leuven, Leuven, Belgium,Department of Neurology, University Hospitals Leuven, Leuven, Belgium
| | - Ph. Demaerel
- Department of Radiology, University Hospitals Leuven, Leuven, Belgium,Department of Imaging & Pathology, Translational MRI, KU Leuven, Leuven, Belgium
| |
Collapse
|
6
|
Delanaye P, Dubois B, Cavalier E, Jouret F. [Diagnostic approach to chronic kidney disease]. Rev Med Liege 2022; 77:249-252. [PMID: 35389010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Chronic kidney disease (CKD) affects ~7 % of the general population and is burdened with significant morbidity and mortality, especially cardiovascular disease. At the terminal stage, CKD requires demanding and costly treatments for the patient and the society, such as dialysis or kidney transplantation. The symptomatology of CKD is poor and unspecific, which complicates the identification and early management of patients with CKD. Diagnostic criteria for CKD include (1) renal morphological abnormality; and/or (2) proteinuria superior to150 mg/g creatinine; and/or (3) glomerular filtration rate (GFR) inferior to 60 ml/min/ 1.73 m². The persistence of these abnormalities for more than 3 months indicates the chronicity of the renal damage. Starting from an exemplary clinical case, we detail the diagnostic steps when faced with a suspicion of CKD.
Collapse
Affiliation(s)
- P Delanaye
- Service de Néphrologie, Dialyse et Transplantation, CHU Liège, Belgique
- Service de Néphrologie, Dialyse, Aphérèse, Hôpital Universitaire Carémeau, Nîmes, France
| | - B Dubois
- Service de Néphrologie, Dialyse et Transplantation, CHU Liège, Belgique
| | - E Cavalier
- Service de Chimie Médicale, ULiège, Belgique
| | - F Jouret
- Service de Néphrologie, Dialyse et Transplantation, CHU Liège, Belgique
- Laboratoire de Recherche Translationnelle en Néphrologie (LTRN), GIGA Sciences Cardio-vasculaires, ULiège, Belgique
| |
Collapse
|
7
|
Gonthier R, Adolphe M, Michel JP, Bringer J, Dubois B, Lecomte D, Milliez J, Vellas B. Rapport 22-02. Après la crise COVID, quelles solutions pour l’EHPAD de demain ? Bulletin de l'Académie Nationale de Médecine 2022; 206:457-465. [PMID: 35221338 PMCID: PMC8857757 DOI: 10.1016/j.banm.2022.02.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Le vieillissement de notre population génère des situations de grande vulnérabilité et de dépendance. Le maintien à domicile demeure habituellement la meilleure réponse pour respecter la volonté de la personne, le souhait de la famille et l’intérêt de la société. Il existe cependant un nombre important de situations où la prise en charge dans un établissement d’hébergement pour personnes âgées dépendantes (EHPAD) s’avère nécessaire. La pandémie de COVID-19 a mis sur le devant de la scène les EHPAD et leurs limites pour assurer des soins de qualité. Pour analyser la place actuelle des EHPAD dans la filière de soin et pour comprendre leurs difficultés de fonctionnement, il paraît indispensable de décrire les mutations accélérées qu’ont connues les EHPAD depuis leur création en 1999, puis, à la lumière de la crise actuelle, d’élaborer des pistes pour développer une vision positive du rôle que ces établissements ont à assurer dans le futur.
Collapse
|
8
|
Marien A, Sedefoglu H, Dubois B, Maljean J, Francis F, Berben G, Guillet S, Morin JF, Fumière O, Debode F. Detection of Alphitobius diaperinus by Real-Time Polymerase Chain Reaction With a Single-Copy Gene Target. Front Vet Sci 2022; 9:718806. [PMID: 35356786 PMCID: PMC8959938 DOI: 10.3389/fvets.2022.718806] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Accepted: 01/10/2022] [Indexed: 01/06/2023] Open
Abstract
Use of edible insects as an alternative source of proteins in food and feed is increasing. These last years, numerous companies in Europe have started producing insects for food and feed purposes. In the European Union, the use of edible insects for human consumption falls within Regulation (EU) No. 2015/2283 on novel foods. For feed, Commission Regulation (EU) 2017/893 authorizes seven insect species as processed animal proteins for aquaculture. Methods of authentication are required to check the conformity of the products. In this study, we propose a real-time polymerase chain reaction (PCR) method for the specific detection of the lesser mealworm (Alphitobius diaperinus), one of the species included in the shortlist of authorized insects. The selected target is the cadherin gene with a single-copy (per haploid genome) illustrated by our experimental evidence. The PCR test amplified a 134-bp fragment of the cadherin gene. The qualitative method was assessed toward several performance criteria. Specificity was checked against 54 insect species next to other animal and plant species. The sensitivity, efficiency, robustness, and transferability of the PCR assay were also successfully tested. Finally, the applicability of the test was assessed on real-life processed samples (industrial meals) of A. diaperinus. The study also showed that there seems to be a huge confusion on the correct labeling of the marketed mealworms. We did not succeed to get Alphitobius laevigatus samples. They all appeared to belong to the A. diaperinus taxon.
Collapse
Affiliation(s)
- Aline Marien
- Quality and Authentication of Agricultural Products Unit, Knowledge and Valorization of Agricultural Products Department, Walloon Agricultural Research Centre, Gembloux, Belgium
- *Correspondence: Aline Marien
| | - Hamza Sedefoglu
- Haute Ecole Louvain-en-Hainaut, Montignies-sur-Sambre, Belgium
| | - Benjamin Dubois
- Quality and Authentication of Agricultural Products Unit, Knowledge and Valorization of Agricultural Products Department, Walloon Agricultural Research Centre, Gembloux, Belgium
| | - Julien Maljean
- Quality and Authentication of Agricultural Products Unit, Knowledge and Valorization of Agricultural Products Department, Walloon Agricultural Research Centre, Gembloux, Belgium
| | - Frédéric Francis
- Functional and Evolutionary Entomology, Gembloux Agro-Bio Tech, ULiège, Gembloux, Belgium
| | - Gilbert Berben
- Quality and Authentication of Agricultural Products Unit, Knowledge and Valorization of Agricultural Products Department, Walloon Agricultural Research Centre, Gembloux, Belgium
| | | | | | - Olivier Fumière
- Quality and Authentication of Agricultural Products Unit, Knowledge and Valorization of Agricultural Products Department, Walloon Agricultural Research Centre, Gembloux, Belgium
| | - Frédéric Debode
- Biological Engineering Unit, Life Sciences Department, Walloon Agricultural Research Centre, Gembloux, Belgium
| |
Collapse
|
9
|
Résimont G, Dubois B, Grosch S, Bovy C, Collart F, Krzesinski JM. [COVID-19 inside dialysis units]. Rev Med Liege 2020; 75:41-47. [PMID: 33211421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
COVID-19 has been the center of global attention and concern for the last months. Patients undergoing dialysis and especially those treated at the hospital are likely to be infected, due to their mandatory presence at the hospital several times a week and due to their intrinsic fragility in regard of chronic kidney disease, often an older age, and the presence of many associated comorbidities. Thereby, patients with chonic kidney disease treated by haemodialysis have higher odds of a more severe COVID-19 infection with a high mortality rate. Prevention is thus a high priority for these patients.
Collapse
Affiliation(s)
- G Résimont
- Service de Néphrologie, Dialyse, Transplantation rénale, ULiège, CHU Liège, Belgique
| | - B Dubois
- Service de Néphrologie, Dialyse, Transplantation rénale, ULiège, CHU Liège, Belgique
| | - S Grosch
- Service de Néphrologie, Dialyse, Transplantation rénale, ULiège, CHU Liège, Belgique
| | - C Bovy
- Service de Néphrologie, Dialyse, Transplantation rénale, ULiège, CHU Liège, Belgique
| | - F Collart
- Service de Néphrologie et Dialyse, CHU Brugmann, Bruxelles, Belgique
| | - J M Krzesinski
- Service de Néphrologie, Dialyse, Transplantation rénale, ULiège, CHU Liège, Belgique
| |
Collapse
|
10
|
Smets I, Verelst S, Meyfroidt G, Van Wijngaerden E, Wilmer A, van Loon J, Lagrou K, Dubois B. Community-acquired bacterial meningitis in adults: emergency department management protocol. Acta Neurol Belg 2020; 120:1033-1043. [PMID: 32666505 DOI: 10.1007/s13760-020-01428-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Accepted: 06/30/2020] [Indexed: 10/23/2022]
Abstract
Acute bacterial meningitis (ABM) is a rare but disabling infectious condition that requires a performant multidisciplinary management approach. Between 70 and 90 adult patients are diagnosed with community-acquired ABM in Belgium annually, and reported case fatality rates range from 17 to 40%. The currently available guidelines provide evidence-based guidance on how to manage this disease. However, these guidelines do not translate the evidence to the daily practice at the emergency department in a Belgian healthcare context. We created a taskforce in University Hospitals Leuven consisting of experts with complementary expertise in managing this disease: neurology, neurosurgery, intensive care medicine, microbiology and infectious diseases. The taskforce agreed upon a flowchart containing seven management steps encompassing all relevant phases in emergency ABM management. In addition to the focus on timely and adequate initiation of antimicrobial treatment, the flowchart and protocol also provide guidance on practical hurdles such as how to assess the safety of performing a lumbar puncture and when to refer patients to the intensive care department. This protocol was implemented in University Hospitals Leuven and fosters inter-disciplinary coordination of ABM care.
Collapse
|
11
|
|
12
|
Volkening A, Abbott MR, Chandra N, Dubois B, Lim F, Sexton D, Sandstede B. Modeling Stripe Formation on Growing Zebrafish Tailfins. Bull Math Biol 2020; 82:56. [PMID: 32356149 DOI: 10.1007/s11538-020-00731-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 04/03/2020] [Indexed: 12/26/2022]
Abstract
As zebrafish develop, black and gold stripes form across their skin due to the interactions of brightly colored pigment cells. These characteristic patterns emerge on the growing fish body, as well as on the anal and caudal fins. While wild-type stripes form parallel to a horizontal marker on the body, patterns on the tailfin gradually extend distally outward. Interestingly, several mutations lead to altered body patterns without affecting fin stripes. Through an exploratory modeling approach, our goal is to help better understand these differences between body and fin patterns. By adapting a prior agent-based model of cell interactions on the fish body, we present an in silico study of stripe development on tailfins. Our main result is a demonstration that two cell types can produce stripes on the caudal fin. We highlight several ways that bone rays, growth, and the body-fin interface may be involved in patterning, and we raise questions for future work related to pattern robustness.
Collapse
Affiliation(s)
- A Volkening
- NSF-Simons Center for Quantitative Biology, Northwestern University, Evanston, IL, USA.
| | - M R Abbott
- Mathematics, Statistics, and Computer Science, Macalester College, St. Paul, MN, USA
| | - N Chandra
- Division of Applied Mathematics, Brown University, Providence, RI, USA
| | - B Dubois
- Division of Applied Mathematics, Brown University, Providence, RI, USA
| | - F Lim
- Division of Applied Mathematics, Brown University, Providence, RI, USA
| | - D Sexton
- Department of Mathematics, University of Idaho, Moscow, ID, USA
| | - B Sandstede
- Division of Applied Mathematics, Brown University, Providence, RI, USA
- Data Science Initiative, Brown University, Providence, RI, USA
| |
Collapse
|
13
|
Dubois B, Bombois S, Villain N, Teichmann M, Epelbaum S, Migliaccio R, Genthon R, Verrat B, Lesoil C, Levy M, Le Ber I, Levy R. [Toward a preventive management Alzheimer's disease]. Bull Acad Natl Med 2020; 204:583-588. [PMID: 32322104 PMCID: PMC7172758 DOI: 10.1016/j.banm.2020.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Accepted: 04/10/2020] [Indexed: 11/03/2022]
Abstract
Les démences et la maladie d’Alzheimer (MA), en particulier, vont devenir de plus en plus un enjeu de santé publique. Trois données importantes peuvent cependant modifier le poids de ces pathologies : (1) de simples mesures d’hygiène de vie (contrôle de facteurs de risque vasculaire, activité physique et stimulation cognitive) instaurées chez les jeunes adultes ont un impact sur un déclin cognitif ultérieur ; (2) chez des sujets âgés à risque, ces mêmes dispositions retardent l’entrée dans la maladie et (3) enfin et pour la première fois, un anticorps anti-amyloïde aurait montré un effet significatif sur l’évolution de la MA chez des patients au stade débutant. Il ressort de ces travaux qu’il faut se préparer à reconsidérer la stratégie de prise en charge des troubles cognitifs, qu’ils soient mineurs ou majeurs, et de la MA en particulier. L’entrée des patients dans le parcours de soins reste aujourd’hui trop tardive. La solution est d’agir plus précocement, voire de façon préventive. Il faut développer une offre de soins adaptée à cette situation nouvelle afin d’agir sur la maladie le plus tôt possible, fondée sur : 1) des algorithmes prédictifs pour déterminer chez les sujets sans symptômes spécifiques ceux qui seront à risque de développer une pathologie dégénérative; ces algorithmes devront être mis au point à partir de données démographiques, familiales, cognitives, génomiques et biologiques, comme celles recueillies dans le projet « Santé-Cerveau » développé en partenariat avec l’ARS et les médecins généralistes ; 2) le renforcement des activités de prévention dans les 450 centres mémoire de proximité disponibles en France et les 26 CM2R et 3) la transformation de quelques-uns de ces centres experts en « cliniques de prévention de la démence » pour tester les mesures de prévention, initier des programmes d’éducation thérapeutique multidomaine et les valider, communiquer sur le risque, répondre à la demande de sujets inquiets et déterminer, chez ceux-ci, à l’aide des algorithmes, le niveau de risque qu’ils ont de déclarer une MA dans les mois et années qui viennent, en tenant compte de la compétition entre les risques. On peut ainsi se préparer à faire bénéficier précocement les uns et les autres des traitements pharmacologiques susceptibles d’exister.
Collapse
Affiliation(s)
- B Dubois
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Sorbonne-Université, Paris, France.,Centre national de référence « maladie Alzheimer Jeune ».,Centre national de référence « démences rares et précoces »
| | - S Bombois
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Centre national de référence « maladie Alzheimer Jeune »
| | - N Villain
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Sorbonne-Université, Paris, France
| | - M Teichmann
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Centre national de référence « démences rares et précoces »
| | - S Epelbaum
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Centre national de référence « maladie Alzheimer Jeune »
| | - R Migliaccio
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France
| | - R Genthon
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - B Verrat
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - C Lesoil
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - M Levy
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - I Le Ber
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Centre national de référence « démences rares et précoces »
| | - R Levy
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Sorbonne-Université, Paris, France.,Centre national de référence « démences rares et précoces »
| |
Collapse
|
14
|
Demily C, Attala N, Fouldrin G, Czernecki V, Ménard JF, Lamy S, Dubois B, Thibaut F. The Emotional Stroop task: A comparison between schizophrenic subjects and controls. Eur Psychiatry 2020; 25:75-9. [DOI: 10.1016/j.eurpsy.2009.02.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2008] [Revised: 01/30/2009] [Accepted: 02/01/2009] [Indexed: 10/20/2022] Open
Abstract
AbstractThe colour-word Emotional Stroop task (ES task) has been proposed to assess the interferences between emotion and attention. Using this task, first, we examined how attention (using reaction times) can be modified by emotionally relevant words in schizophrenics as compared with controls as a function of the emotional significance of the word; second, we tested the assumption that schizophrenics with the most negative symptoms will show higher impairment in relationship to negative emotional words. In general, schizophrenics were slower to react. In both groups, mean reaction times were slower for emotional as compared with neutral words. No significant differences were observed between negative and positive words either in schizophrenics (n = 21) or in controls (n = 20). Even in the most negative schizophrenic patients, there were no differences between negative and positive words. There were no significant interactions between type of stimulus and any clinical variables (PANSS negative or non negative categorization, etc.). Also, there were no statistically significant correlations between reaction times and neuroleptic dosage or anhedonia scores. In conclusion, schizophrenia patients showed the same degree of interference from emotional words as compared with controls. Moreover, patients with a higher level of negative symptoms did not differently experience positive and negative words.
Collapse
|
15
|
Sabbagh MN, Boada M, Borson S, Chilukuri M, Dubois B, Ingram J, Iwata A, Porsteinsson AP, Possin KL, Rabinovici GD, Vellas B, Chao S, Vergallo A, Hampel H. Early Detection of Mild Cognitive Impairment (MCI) in Primary Care. J Prev Alzheimers Dis 2020; 7:165-170. [PMID: 32463069 DOI: 10.14283/jpad.2020.21] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2024]
Abstract
Mild cognitive impairment (MCI) is significantly misdiagnosed in the primary care setting due to multi-dimensional frictions and barriers associated with evaluating individuals' cognitive performance. To move toward large-scale cognitive screening, a global panel of clinicians and cognitive neuroscientists convened to elaborate on current challenges that hamper widespread cognitive performance assessment. This report summarizes a conceptual framework and provides guidance to clinical researchers and test developers and suppliers to inform ongoing refinement of cognitive evaluation. This perspective builds upon a previous article in this series, which outlined the rationale for and potentially against efforts to promote widespread detection of MCI. This working group acknowledges that cognitive screening by default is not recommended and proposes large-scale evaluation of individuals with a concern or interest in their cognitive performance. Such a strategy can increase the likelihood to timely and effective identification and management of MCI. The rising global incidence of AD demands innovation that will help alleviate the burden to healthcare systems when coupled with the potentially near-term approval of disease-modifying therapies. Additionally, we argue that adequate infrastructure, equipment, and resources urgently should be integrated in the primary care setting to optimize the patient journey and accommodate widespread cognitive evaluation.
Collapse
Affiliation(s)
- M N Sabbagh
- Marwan N. Sabbagh, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, ; Tel.: (702) 483-6029; Fax: (702) 722-6584
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Sabbagh MN, Boada M, Borson S, Doraiswamy PM, Dubois B, Ingram J, Iwata A, Porsteinsson AP, Possin KL, Rabinovici GD, Vellas B, Chao S, Vergallo A, Hampel H. Early Detection of Mild Cognitive Impairment (MCI) in an At-Home Setting. J Prev Alzheimers Dis 2020; 7:171-178. [PMID: 32463070 DOI: 10.14283/jpad.2020.22] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Emerging digital tools have the potential to enable a new generation of qualitative and quantitative assessment of cognitive performance. Moreover, the ubiquity of consumer electronics, such as smartphones and tablets, can be harnessed to support large-scale self-assessed cognitive screening with benefit to healthcare systems and consumers. A wide variety of apps, wearables, and new digital technologies are either available or in development for the detection of mild cognitive impairment (MCI), a risk factor for dementia. Two categories of novel methodologies may be considered: passive technologies (which monitor a user's behavior without active user input) and interactive assessments (which require active user input). Such examinations can be self-administered, supervised by a caregiver, or conducted by an informant at home or outside of a clinical setting. These direct-to-consumer tools have the potential to sidestep barriers associated with cognitive evaluation in primary care, thus improving access to cognitive assessments. Although direct-to-consumer cognitive assessment is associated with its own barriers, including test validation, user experience, and technological concerns, it is conceivable that these issues can be addressed so that a large-scale, self-assessed cognitive evaluation that would represent an initial cognitive screen may be feasible in the future.
Collapse
Affiliation(s)
- M N Sabbagh
- Marwan N. Sabbagh, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, ; Tel.: (702) 483-6029; Fax: (702) 722-6584
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Manrique JA, Lopez-Reyes G, Cousin A, Rull F, Maurice S, Wiens RC, Madsen MB, Madariaga JM, Gasnault O, Aramendia J, Arana G, Beck P, Bernard S, Bernardi P, Bernt MH, Berrocal A, Beyssac O, Caïs P, Castro C, Castro K, Clegg SM, Cloutis E, Dromart G, Drouet C, Dubois B, Escribano D, Fabre C, Fernandez A, Forni O, Garcia-Baonza V, Gontijo I, Johnson J, Laserna J, Lasue J, Madsen S, Mateo-Marti E, Medina J, Meslin PY, Montagnac G, Moral A, Moros J, Ollila AM, Ortega C, Prieto-Ballesteros O, Reess JM, Robinson S, Rodriguez J, Saiz J, Sanz-Arranz JA, Sard I, Sautter V, Sobron P, Toplis M, Veneranda M. SuperCam Calibration Targets: Design and Development. Space Sci Rev 2020; 216:138. [PMID: 33281235 PMCID: PMC7691312 DOI: 10.1007/s11214-020-00764-w] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Accepted: 11/09/2020] [Indexed: 05/09/2023]
Abstract
SuperCam is a highly integrated remote-sensing instrumental suite for NASA's Mars 2020 mission. It consists of a co-aligned combination of Laser-Induced Breakdown Spectroscopy (LIBS), Time-Resolved Raman and Luminescence (TRR/L), Visible and Infrared Spectroscopy (VISIR), together with sound recording (MIC) and high-magnification imaging techniques (RMI). They provide information on the mineralogy, geochemistry and mineral context around the Perseverance Rover. The calibration of this complex suite is a major challenge. Not only does each technique require its own standards or references, their combination also introduces new requirements to obtain optimal scientific output. Elemental composition, molecular vibrational features, fluorescence, morphology and texture provide a full picture of the sample with spectral information that needs to be co-aligned, correlated, and individually calibrated. The resulting hardware includes different kinds of targets, each one covering different needs of the instrument. Standards for imaging calibration, geological samples for mineral identification and chemometric calculations or spectral references to calibrate and evaluate the health of the instrument, are all included in the SuperCam Calibration Target (SCCT). The system also includes a specifically designed assembly in which the samples are mounted. This hardware allows the targets to survive the harsh environmental conditions of the launch, cruise, landing and operation on Mars during the whole mission. Here we summarize the design, development, integration, verification and functional testing of the SCCT. This work includes some key results obtained to verify the scientific outcome of the SuperCam system.
Collapse
Affiliation(s)
- J. A. Manrique
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - G. Lopez-Reyes
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - A. Cousin
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - F. Rull
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - S. Maurice
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - R. C. Wiens
- Los Alamos National Laboratory, Los Alamos, NM USA
| | - M. B. Madsen
- Niels Bohr Institute (NBI), University of Copenhagen, Copenhagen, Denmark
| | | | - O. Gasnault
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - J. Aramendia
- University of the Basque Country (UPV/EHU), Leioa, Spain
| | - G. Arana
- University of the Basque Country (UPV/EHU), Leioa, Spain
| | - P. Beck
- CNRS, Institut de Planetologie et d’Astrophysique de Grenoble (IPAG), Universite Grenoble Alpes, Saint-Martin d’Heres, France
| | - S. Bernard
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie (IMPMC), CNRS, MNHN, Sorbonne Université, Paris, France
| | - P. Bernardi
- Laboratoire d’Etudes Spatiales et d’Instrumentation en Astrophysique, Observatoire de Paris-PSL, CNRS, Sorbonne Université, Université de Paris, Meudon, France
| | - M. H. Bernt
- Niels Bohr Institute (NBI), University of Copenhagen, Copenhagen, Denmark
| | - A. Berrocal
- Ingeniería de Sistemas para la Defensa de España S.A. (ISDEFE), Madrid, Spain
| | - O. Beyssac
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie (IMPMC), CNRS, MNHN, Sorbonne Université, Paris, France
| | - P. Caïs
- Laboratoire d’astrophysique de Bordeaux, CNRS, Univ. Bordeaux, Bordeaux, France
| | - C. Castro
- Added Value Solutions (AVS), Elgóibar, Spain
| | - K. Castro
- University of the Basque Country (UPV/EHU), Leioa, Spain
| | - S. M. Clegg
- Los Alamos National Laboratory, Los Alamos, NM USA
| | | | - G. Dromart
- Univ Lyon, ENSL, CNRS, LGL-TPE, Univ Lyon 1, 69007 Lyon, France
| | - C. Drouet
- CIRIMAT, Université de Toulouse, CNRS/UT3/INP, Ensiacet, Toulouse, France
| | - B. Dubois
- Observatoire Midi-Pyrénées, Toulouse, France
| | - D. Escribano
- Instituto Nacional de Técnica Aeroespacial, Torrejón de Ardoz, Spain
| | - C. Fabre
- GeoRessources, Vandoeuvre les Nancy, France
| | | | - O. Forni
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - V. Garcia-Baonza
- Instituto de Geociencias CSIC, Universidad Complutense de Madrid, Madrid, Spain
| | - I. Gontijo
- Jet Propulsion Laboratory, Pasadena, CA USA
| | - J. Johnson
- Applied Physics Laboratory, Johns Hopkins University, Laurel, MD USA
| | - J. Laserna
- University of Malaga (UMA), Málaga, Spain
| | - J. Lasue
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - S. Madsen
- Jet Propulsion Laboratory, Pasadena, CA USA
| | - E. Mateo-Marti
- Centro de Astrobiología-CSIC-INTA, Torrejón de Ardoz, Spain
| | - J. Medina
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - P.-Y. Meslin
- Institut de Recherche en Astrophysique et Planétologie (IRAP), CNRS, CNES, Université de Toulouse, Toulouse, France
| | - G. Montagnac
- Univ Lyon, ENSL, CNRS, LGL-TPE, Univ Lyon 1, 69007 Lyon, France
| | - A. Moral
- Instituto Nacional de Técnica Aeroespacial, Torrejón de Ardoz, Spain
| | - J. Moros
- University of Malaga (UMA), Málaga, Spain
| | - A. M. Ollila
- Los Alamos National Laboratory, Los Alamos, NM USA
| | - C. Ortega
- Added Value Solutions (AVS), Elgóibar, Spain
| | | | - J. M. Reess
- Laboratoire d’Etudes Spatiales et d’Instrumentation en Astrophysique, Observatoire de Paris-PSL, CNRS, Sorbonne Université, Université de Paris, Meudon, France
| | - S. Robinson
- Los Alamos National Laboratory, Los Alamos, NM USA
| | - J. Rodriguez
- Ingeniería de Sistemas para la Defensa de España S.A. (ISDEFE), Madrid, Spain
| | - J. Saiz
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - J. A. Sanz-Arranz
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| | - I. Sard
- Added Value Solutions (AVS), Elgóibar, Spain
| | - V. Sautter
- Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie (IMPMC), CNRS, MNHN, Sorbonne Université, Paris, France
| | - P. Sobron
- SETI Institute, Mountain View, CA USA
| | - M. Toplis
- Observatoire Midi-Pyrénées, Toulouse, France
| | - M. Veneranda
- Unidad Asocida UVA-CSIC-CAB, University of Valladolid (UVA), Valladolid, Spain
| |
Collapse
|
18
|
Sabbagh MN, Boada M, Borson S, Chilukuri M, Doraiswamy PM, Dubois B, Ingram J, Iwata A, Porsteinsson AP, Possin KL, Rabinovici GD, Vellas B, Chao S, Vergallo A, Hampel H. Rationale for Early Diagnosis of Mild Cognitive Impairment (MCI) Supported by Emerging Digital Technologies. J Prev Alzheimers Dis 2020; 7:158-164. [PMID: 32463068 DOI: 10.14283/jpad.2020.19] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Disease-modifying pharmacotherapies for Alzheimer's Disease (AD) are currently in late-stage clinical development; once approved, new healthcare infrastructures and services, including primary healthcare, will be necessary to accommodate a huge demand for early and large-scale detection of AD. The increasing global accessibility of digital consumer electronics has opened up new prospects for early diagnosis and management of mild cognitive impairment (MCI) with particular regard to AD. This new wave of innovation has spurred research in both academia and industry, aimed at developing and validating a new "digital generation" of tools for the assessment of the cognitive performance. In light of this paradigm shift, an international working group (the Global Advisory Group on Future MCI Care Pathways) convened to elaborate on how digital tools may be optimally integrated in screening-diagnostic pathways of AD The working group developed consensus perspectives on new algorithms for large-scale screening, detection, and diagnosis of individuals with MCI within primary medical care delivery. In addition, the expert panel addressed operational aspects concerning the implementation of unsupervised at-home testing of cognitive performance. The ultimate intent of the working group's consensus perspectives is to provide guidance to developers of cognitive tests and tools to facilitate the transition toward globally accessible cognitive screening aimed at the early detection, diagnosis, and management of MCI due to AD.
Collapse
Affiliation(s)
- M N Sabbagh
- Marwan N. Sabbagh, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, ; Tel.: (702) 483-6029; Fax: (702) 722-6584
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Van Horebeek L, Dubois B, Goris A. Somatic Variants: New Kids on the Block in Human Immunogenetics. Trends Genet 2019; 35:935-947. [PMID: 31668909 DOI: 10.1016/j.tig.2019.09.005] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 09/23/2019] [Accepted: 09/27/2019] [Indexed: 01/21/2023]
Abstract
Somatic variants are not inherited but acquired during an individual's lifetime, and individuals are increasingly considered as complex mosaics of genetically distinct cells. Whereas this concept is long-recognized in cancer, this review focuses on the growing role of somatic variants in immune cells in nonmalignant immune-related disorders, such as primary immunodeficiency and autoimmune diseases. Older case reports described somatic variants early in development, leading to large numbers of affected cells and severe phenotypes. Thanks to technological evolution, it is now feasible to detect somatic variants occurring later in life and affecting fewer cells. Hence, only recently is the scale at which somatic variants contribute to monogenic diseases being uncovered and is their contribution to complex diseases being explored systematically.
Collapse
Affiliation(s)
- L Van Horebeek
- KU Leuven Department of Neurosciences, Laboratory for Neuroimmunology, 3000 Leuven, Belgium; Leuven Brain Institute, 3000 Leuven, Belgium
| | - B Dubois
- KU Leuven Department of Neurosciences, Laboratory for Neuroimmunology, 3000 Leuven, Belgium; Leuven Brain Institute, 3000 Leuven, Belgium; University Hospitals Leuven, Department of Neurology, 3000 Leuven, Belgium
| | - A Goris
- KU Leuven Department of Neurosciences, Laboratory for Neuroimmunology, 3000 Leuven, Belgium; Leuven Brain Institute, 3000 Leuven, Belgium.
| |
Collapse
|
20
|
Escarnot E, Gofflot S, Sinnaeve G, Dubois B, Bertin P, Mingeot D. Reactivity of gluten proteins from spelt and bread wheat accessions towards A1 and G12 antibodies in the framework of celiac disease. Food Chem 2018; 268:522-532. [DOI: 10.1016/j.foodchem.2018.06.094] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Revised: 05/25/2018] [Accepted: 06/19/2018] [Indexed: 11/28/2022]
|
21
|
Dubois B, Bertin P, Hautier L, Muhovski Y, Escarnot E, Mingeot D. Genetic and environmental factors affecting the expression of α-gliadin canonical epitopes involved in celiac disease in a wide collection of spelt (Triticum aestivum ssp. spelta) cultivars and landraces. BMC Plant Biol 2018; 18:262. [PMID: 30382818 PMCID: PMC6211434 DOI: 10.1186/s12870-018-1487-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Accepted: 10/17/2018] [Indexed: 06/08/2023]
Abstract
BACKGROUND Celiac disease (CD) is an autoimmune disorder affecting genetically predisposed individuals whose dietary gluten proteins trigger an inflammatory reaction in the small intestine. Gluten is found in the seeds of cereals like bread wheat (Triticum aestivum ssp. aestivum) and spelt (Triticum aestivum ssp. spelta). The development of new varieties lacking immunogenic peptides is one of the strategies currently investigated to address the CD problem. Among gluten proteins, α-gliadins display the strongest immunogenicity with four main T-cell stimulatory epitopes. The objective of this work was to study the expression of α-gliadin epitopes related to CD in a wide collection of 121 spelt accessions (landraces and varieties, spring and winter accessions) from different provenances, and to analyze the correlation between the presence of epitope sequences in gDNA and their expression (cDNA). The effect of environmental factors (harvest year and N fertilization) on the epitope expression was also investigated. RESULTS TaqMan probes targeting the canonical form of the epitopes were used to evaluate the epitope expression levels. Significant variations in the amount of epitope transcripts were identified between accessions and according to the provenances. Spring accessions showed a significantly higher immunogenicity than winter ones and no influence of spelt breeding on the epitope expression levels could be assessed when comparing landraces and varieties from Northwestern Europe. No correlation was observed between quantitative PCR results obtained from cDNA and gDNA for 45 accessions tested, stressing the need to use markers focusing on epitope transcripts rather than on genomic sequences. A relative stability of the amount of epitopes expressed by a same accession across four harvest years was detected. The fertilization strategy, evaluated through seven N fertilization modalities applied to two commercial spelt varieties, did not influence the epitope expression of the first variety, whereas it had a slight effect for the second one. CONCLUSIONS The results obtained in this work showed that the CD-related epitope expression greatly fluctuated among the spelt accessions studied. This expression was not correlated to the epitope genomic occurrence and environmental factors had almost no influence on the amount of epitope transcripts.
Collapse
Affiliation(s)
- Benjamin Dubois
- Unit of Bioengineering, Department of Life Sciences, Walloon Agricultural Research Center, Gembloux, Belgium
- Earth and Life Institute-Agronomy, Catholic University of Louvain, Louvain-la-Neuve, Belgium
| | - Pierre Bertin
- Earth and Life Institute-Agronomy, Catholic University of Louvain, Louvain-la-Neuve, Belgium
| | - Louis Hautier
- Unit of Plant protection and ecotoxicology, Department of Life Sciences, Walloon Agricultural Research Center, Gembloux, Belgium
| | - Yordan Muhovski
- Unit of Bioengineering, Department of Life Sciences, Walloon Agricultural Research Center, Gembloux, Belgium
| | - Emmanuelle Escarnot
- Unit of Breeding and biodiversity, Department of Life Sciences, Walloon Agricultural Research Center, Gembloux, Belgium
| | - Dominique Mingeot
- Unit of Bioengineering, Department of Life Sciences, Walloon Agricultural Research Center, Gembloux, Belgium
| |
Collapse
|
22
|
Krzesinski F, Delanaye P, Dubois B, Delcour A, Krzesinski JM, Lancellotti P. P3511Interest and potential risk of increasing concentration potassium in the dialysis bath in patients on chronic hemodialysis. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- F Krzesinski
- University Hospital of Liege (CHU), Cardiology, Liege, Belgium
| | - P Delanaye
- University Hospital of Liege (CHU), Nephrology, Liege, Belgium
| | - B Dubois
- University Hospital of Liege (CHU), Nephrology, Liege, Belgium
| | - A Delcour
- University Hospital of Liege (CHU), Cardiology, Liege, Belgium
| | - J M Krzesinski
- University Hospital of Liege (CHU), Nephrology, Liege, Belgium
| | - P Lancellotti
- University Hospital of Liege (CHU), Cardiology, Liege, Belgium
| |
Collapse
|
23
|
Dubois B. Address from the President, February 2018. Rev Neurol (Paris) 2018. [DOI: 10.1016/j.neurol.2018.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
24
|
Carras S, Dubois B, Senecal D, Jais JP, Peoc'h M, Quittet P, Foussard C, Bouabdallah K, Gastinne T, Jourdan E, Sanhes L, Ertault M, Lamy T, Molina L. Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial. Clin Lymphoma Myeloma Leuk 2018; 18:191-198. [PMID: 29502594 DOI: 10.1016/j.clml.2018.01.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Revised: 01/02/2018] [Accepted: 01/16/2018] [Indexed: 11/30/2022]
Abstract
BACKGROUND Patients with advanced stage Hodgkin lymphoma still present unsatisfactory outcomes. PATIENTS AND METHODS The Groupe d'étude des Leucémies Aigues et des Maladies du Sang (GOELAMS) group conducted a prospective multicentric trial (NCT00920153) for advanced stage Hodgkin lymphoma to evaluate a positron emission tomography (PET)-adapted strategy. Patients received an intensive regimen (VABEM [vindesine, doxorubicin, carmustine, etoposide, and methylprednisolone]) in front-line and interim 18FFDG-PET evaluation after 2 courses (PET-2). Patients with negative PET-2 findings received 1 additional course. Patients with positive PET-2 findings underwent early salvage therapy followed by high-dose therapy/autologous stem cell transplantation. RESULTS Fifty-one patients were included. The final complete remission rate was 88%. With a median follow up of 5.3 years, 5-year event-free survival and overall survival rates were 75.3% and 85.3%, respectively, for the whole cohort. Patients who were PET-2-negative had 5-year event-free survival and overall survival rates of, respectively, 77.8% and 88.2% versus 85.1% and 91.7% for patients who were PET-2-positive. CONCLUSION A PET-guided strategy with early salvage therapy and high-dose therapy/autologous stem cell transplantation for patients with interim PET-2-positive findings is safe and feasible and provide similar outcome as patients with a negative PET-2.
Collapse
Affiliation(s)
- Sylvain Carras
- Hematology Department, Grenoble University Hospital, Grenoble, France
| | - Benjamin Dubois
- Nuclear Medicine Department, Grenoble University Hospital, Grenoble, France
| | | | | | - Michel Peoc'h
- Anatomopathology Department, St Etienne University Hospital, Saint-Etienne, France
| | - Philippe Quittet
- Hematology Department, Montpellier University Hospital, Montpellier, France
| | - Charles Foussard
- Hematology Department, Angers University Hospital, Angers, France
| | | | - Thomas Gastinne
- Hematology Department, Nantes University Hospital, Nantes, France
| | - Eric Jourdan
- Hematology Department, Nimes University Hospital, Nimes, France
| | - Laurence Sanhes
- Hematology Department, Perpignan Hospital, Perpignan, France
| | - Marjan Ertault
- Hematology Department, Tours University Hospital, Tours, France
| | - Thierry Lamy
- Hematology Department, Rennes University Hospital, Rennes, France
| | - Lysiane Molina
- Hematology Department, Grenoble University Hospital, Grenoble, France
| |
Collapse
|
25
|
Delanaye P, Lambermont B, Dogné JM, Dubois B, Ghuysen A, Janssen N, Desaive T, Kolh P, D'Orio V, Krzesinski JM. Confirmation of High Cytokine Clearance by Hemofiltration with a Cellulose Triacetate Membrane with Large Pores: An in vivo Study. Int J Artif Organs 2018; 29:944-8. [PMID: 17211815 DOI: 10.1177/039139880602901004] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Objective To confirm in vivo the hypothesis that hemofiltration with a large pore membrane can achieve significant cytokine clearance. Method We used a well-known animal model of endotoxinic shock (0.5 mg/kg of lipopolysaccharide from Escherichia Coli over a period of 30 mins). Six pigs were hemofiltrated for 3 hours with a large pore membrane (78 Å pore, 80 kDa cut off) (Sureflux FH 70, Nipro, Osaka, Japan). The ultrafiltration rate was 45 ml/kg/min. Samples were taken from arterial, venous line and in the ultrafiltrate at T120 and T240. We measured concentrations of interleukin 6, interleukin 10 and albumin. Results At T120 and T240, the IL-6 clearances were 22 ± 7 and 15 ± 3 ml/min, respectively. The IL-6 sieving coefficients were 0.97 and 0.7 at T120 and T240, respectively. At T120 and T240, the IL-10 clearances were 14 ± 4 and 10 ± 7 ml/min, respectively. The sieving coefficients were 0.63 and 0.45 at T120 and T240, respectively. The concentrations of IL-6 and IL-10 were the same at T0 and T240. At T60 and T240, the plasmatic albumin concentrations were 24 ± 4 g/L and 23 ± 4 g/L, respectively (p = 0.13). Conclusions In this animal model of endotoxinic shock, we confirm the high cytokine clearance observed when hemofiltration is applied to a large pore membrane. The loss of albumin seems negligible. The impact of such clearances on hemodynamic stability and survival remains to be proved.
Collapse
Affiliation(s)
- P Delanaye
- Department of Nephrology, University of Liege, Liege - Belgium.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Dubois B, Rodgerson D. What Is Your Diagnosis? J Am Vet Med Assoc 2017; 251:1127-1130. [PMID: 29099255 DOI: 10.2460/javma.251.10.1127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
27
|
Guillon J, Attal Y, Colliot O, La Corte V, Dubois B, Schwartz D, Chavez M, De Vico Fallani F. Loss of brain inter-frequency hubs in Alzheimer's disease. Sci Rep 2017; 7:10879. [PMID: 28883408 PMCID: PMC5589939 DOI: 10.1038/s41598-017-07846-w] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Accepted: 06/29/2017] [Indexed: 01/05/2023] Open
Abstract
Alzheimer's disease (AD) causes alterations of brain network structure and function. The latter consists of connectivity changes between oscillatory processes at different frequency channels. We proposed a multi-layer network approach to analyze multiple-frequency brain networks inferred from magnetoencephalographic recordings during resting-states in AD subjects and age-matched controls. Main results showed that brain networks tend to facilitate information propagation across different frequencies, as measured by the multi-participation coefficient (MPC). However, regional connectivity in AD subjects was abnormally distributed across frequency bands as compared to controls, causing significant decreases of MPC. This effect was mainly localized in association areas and in the cingulate cortex, which acted, in the healthy group, as a true inter-frequency hub. MPC values significantly correlated with memory impairment of AD subjects, as measured by the total recall score. Most predictive regions belonged to components of the default-mode network that are typically affected by atrophy, metabolism disruption and amyloid-β deposition. We evaluated the diagnostic power of the MPC and we showed that it led to increased classification accuracy (78.39%) and sensitivity (91.11%). These findings shed new light on the brain functional alterations underlying AD and provide analytical tools for identifying multi-frequency neural mechanisms of brain diseases.
Collapse
Affiliation(s)
- J Guillon
- Inria Paris, Aramis project-team, 75013, Paris, France
- CNRS UMR-7225, Sorbonne Universites, UPMC Univ Paris 06, Inserm U-1127, Institut du cerveau et la moelle (ICM), Hopital Pitie-Salpetriere, 75013, Paris, France
| | - Y Attal
- MyBrain Technologies, Paris, France
| | - O Colliot
- Inria Paris, Aramis project-team, 75013, Paris, France
- CNRS UMR-7225, Sorbonne Universites, UPMC Univ Paris 06, Inserm U-1127, Institut du cerveau et la moelle (ICM), Hopital Pitie-Salpetriere, 75013, Paris, France
| | - V La Corte
- Institute of Psychology, University Paris Descartes, Sorbonne Paris Cite, France
- INSERM UMR 894, Center of Psychiatry and Neurosciences, Memory and Cognition Laboratory, Paris, France
| | - B Dubois
- Department of Neurology, Institut de la Memoire et de la Maladie dAlzheimer - IM2A, Paris, France
| | - D Schwartz
- CNRS UMR-7225, Sorbonne Universites, UPMC Univ Paris 06, Inserm U-1127, Institut du cerveau et la moelle (ICM), Hopital Pitie-Salpetriere, 75013, Paris, France
| | - M Chavez
- CNRS UMR-7225, Sorbonne Universites, UPMC Univ Paris 06, Inserm U-1127, Institut du cerveau et la moelle (ICM), Hopital Pitie-Salpetriere, 75013, Paris, France
| | - F De Vico Fallani
- Inria Paris, Aramis project-team, 75013, Paris, France.
- CNRS UMR-7225, Sorbonne Universites, UPMC Univ Paris 06, Inserm U-1127, Institut du cerveau et la moelle (ICM), Hopital Pitie-Salpetriere, 75013, Paris, France.
| |
Collapse
|
28
|
Dubois B, Bertin P, Muhovski Y, Escarnot E, Mingeot D. Development of TaqMan probes targeting the four major celiac disease epitopes found in α-gliadin sequences of spelt ( Triticum aestivum ssp. spelta) and bread wheat ( Triticum aestivum ssp. aestivum). Plant Methods 2017; 13:72. [PMID: 28912827 PMCID: PMC5588674 DOI: 10.1186/s13007-017-0222-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Accepted: 08/31/2017] [Indexed: 06/01/2023]
Abstract
BACKGROUND Celiac disease (CD) is caused by specific sequences of gluten proteins found in cereals such as bread wheat (Triticum aestivum ssp. aestivum) and spelt (T. aestivum ssp. spelta). Among them, the α-gliadins display the highest immunogenicity, with four T-cell stimulatory epitopes. The toxicity of each epitope sequence can be reduced or even suppressed according to the allelic form of each sequence. One way to address the CD problem would be to make use of this allelic variability in breeding programs to develop safe varieties, but tools to track the presence of toxic epitopes are required. The objective of this study was to develop a tool to accurately detect and quantify the immunogenic content of expressed α-gliadins of spelt and bread wheat. RESULTS Four TaqMan probes that only hybridize to the canonical-i.e. toxic-form of each of the four epitopes were developed and their specificity was demonstrated. Six TaqMan probes targeting stable reference genes were also developed and constitute a tool to normalize qPCR data. The probes were used to measure the epitope expression levels of 11 contrasted spelt accessions and three ancestral diploid accessions of bread wheat and spelt. A high expression variability was highlighted among epitopes and among accessions, especially in Asian spelts, which showed lower epitope expression levels than the other spelts. Some discrepancies were identified between the canonical epitope expression level and the global amount of expressed α-gliadins, which makes the designed TaqMan probes a useful tool to quantify the immunogenic potential independently of the global amount of expressed α-gliadins. CONCLUSIONS The results obtained in this study provide useful tools to study the immunogenic potential of expressed α-gliadin sequences from Triticeae accessions such as spelt and bread wheat. The application of the designed probes to contrasted spelt accessions revealed a high variability and interesting low canonical epitope expression levels in the Asian spelt accessions studied.
Collapse
Affiliation(s)
- Benjamin Dubois
- Département Sciences du vivant, Centre wallon de Recherches agronomiques (CRA-W), Chaussée de Charleroi, 234, 5030 Gembloux, Belgium
- Earth and Life Institute – Agronomy, Université catholique de Louvain (UCL), Croix du Sud, 2 bte L7.05.11, 1348 Louvain-la-Neuve, Belgium
| | - Pierre Bertin
- Earth and Life Institute – Agronomy, Université catholique de Louvain (UCL), Croix du Sud, 2 bte L7.05.11, 1348 Louvain-la-Neuve, Belgium
| | - Yordan Muhovski
- Département Sciences du vivant, Centre wallon de Recherches agronomiques (CRA-W), Chaussée de Charleroi, 234, 5030 Gembloux, Belgium
| | - Emmanuelle Escarnot
- Département Sciences du vivant, Centre wallon de Recherches agronomiques (CRA-W), Rue de Liroux, 4, 5030 Gembloux, Belgium
| | - Dominique Mingeot
- Département Sciences du vivant, Centre wallon de Recherches agronomiques (CRA-W), Chaussée de Charleroi, 234, 5030 Gembloux, Belgium
| |
Collapse
|
29
|
Smets I, Van Deun L, Bohyn C, van Pesch V, Vanopdenbosch L, Dive D, Bissay V, Dubois B. Corticosteroids in the management of acute multiple sclerosis exacerbations. Acta Neurol Belg 2017; 117:623-633. [PMID: 28391390 DOI: 10.1007/s13760-017-0772-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Accepted: 03/12/2017] [Indexed: 11/29/2022]
Abstract
Multiple sclerosis (MS) is an autoimmune, inflammatory demyelinating disease of the central nervous system characterized in the majority of the patients by a relapsing-remitting disease course. For decades high-dosage corticosteroids (CS) are considered the cornerstone in the management of acute MS relapses. However, many unanswered questions remain when it comes to the exact modalities of CS administration. In this review on behalf of the Belgian Study Group for MS we define the efficacy of CS in reducing MS-related morbidity and examine whether the effect is different according to type of CS, route of administration, cumulative dosage, timing of initiation and disease course. We also review the use of CS in combination with other MS treatments and during pregnancy and lactation. Furthermore, we delineate the relevant adverse events due to a pulse CS regimen and present a decision tree that can be used when treating MS relapses in clinical practice.
Collapse
Affiliation(s)
- I Smets
- Department of Neurology, University Hospitals Leuven, Herestraat 49, 3000, Louvain, Belgium.
| | - L Van Deun
- Department of Neurology, University Hospitals Brussels, Laarbeeklaan 101, Jette, Belgium
| | - C Bohyn
- Department of Radiology, University Hospitals Leuven, Herestraat 49, Louvain, Belgium
| | - V van Pesch
- Department of Neurology, Cliniques Universitaires Saint-Luc, Hippokrateslaan 10, Sint-Lambrechts-Woluwe, Belgium
| | - L Vanopdenbosch
- Department of Neurology, Hospital AZ Sint-Jan, Ruddershove 10, Brugge, Belgium
| | - D Dive
- Neuroimmunological and Rehabilitation Unit, University Hospitals Liège, Avenue de L'Hòpital 1, Liège, Belgium
| | - V Bissay
- Department of Neurology, University Hospitals Brussels, Laarbeeklaan 101, Jette, Belgium
| | - B Dubois
- Department of Neurology, University Hospitals Leuven, Herestraat 49, 3000, Louvain, Belgium
| |
Collapse
|
30
|
Janel N, Alexopoulos P, Badel A, Lamari F, Camproux AC, Lagarde J, Simon S, Feraudet-Tarisse C, Lamourette P, Arbones M, Paul JL, Dubois B, Potier MC, Sarazin M, Delabar JM. Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease. Transl Psychiatry 2017; 7:e1154. [PMID: 28632203 PMCID: PMC5537644 DOI: 10.1038/tp.2017.123] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2016] [Revised: 04/27/2017] [Accepted: 04/28/2017] [Indexed: 02/07/2023] Open
Abstract
Early identification of Alzheimer's disease (AD) risk factors would aid development of interventions to delay the onset of dementia, but current biomarkers are invasive and/or costly to assess. Validated plasma biomarkers would circumvent these challenges. We previously identified the kinase DYRK1A in plasma. To validate DYRK1A as a biomarker for AD diagnosis, we assessed the levels of DYRK1A and the related markers brain-derived neurotrophic factor (BDNF) and homocysteine in two unrelated AD patient cohorts with age-matched controls. Receiver-operating characteristic curves and logistic regression analyses showed that combined assessment of DYRK1A, BDNF and homocysteine has a sensitivity of 0.952, a specificity of 0.889 and an accuracy of 0.933 in testing for AD. The blood levels of these markers provide a diagnosis assessment profile. Combined assessment of these three markers outperforms most of the previous markers and could become a useful substitute to the current panel of AD biomarkers. These results associate a decreased level of DYRK1A with AD and challenge the use of DYRK1A inhibitors in peripheral tissues as treatment. These measures will be useful for diagnosis purposes.
Collapse
Affiliation(s)
- N Janel
- Université Paris Diderot, Sorbonne Paris Cité, Unité de Biologie Fonctionnelle et Adaptative, Paris, France
| | - P Alexopoulos
- Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
- Department of Psychiatry, University Hospital of Rion, University of Patras, Patras, Greece
| | - A Badel
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - F Lamari
- Department of Metabolic Biochemistry, Groupe Hospitalier Pitié Salpêtrière-Charles Foix, Paris, France
| | - A C Camproux
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - J Lagarde
- Unit of Neurology of Memory and Langage, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France
| | - S Simon
- CEA, DSV, iBiTec-S, Laboratoire d'études et de recherches en immunoanalyse, Gif-sur-Yvette, France
| | - C Feraudet-Tarisse
- CEA, DSV, iBiTec-S, Laboratoire d'études et de recherches en immunoanalyse, Gif-sur-Yvette, France
| | - P Lamourette
- CEA, DSV, iBiTec-S, Laboratoire d'études et de recherches en immunoanalyse, Gif-sur-Yvette, France
| | - M Arbones
- Instituto de Biología Molecular de Barcelona (CSIC), Barcelona, Spain
| | - J L Paul
- AP-HP, Hôpital Européen Georges Pompidou, Service de Biochimie, Paris, France
| | - B Dubois
- Alzheimer Institute (MB, LCdS, BD, MS), Department of Neurology, Hôpital Pitié-Salpêtrière (Assistance Publique—Hôpitaux de Paris), Paris, France
| | - M C Potier
- INSERM U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMRS 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France
| | - M Sarazin
- Unit of Neurology of Memory and Langage, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France
| | - J M Delabar
- INSERM U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMRS 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France
| |
Collapse
|
31
|
Hampel H, O’Bryant SE, Durrleman S, Younesi E, Rojkova K, Escott-Price V, Corvol JC, Broich K, Dubois B, Lista S. A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric 2017; 20:107-118. [DOI: 10.1080/13697137.2017.1287866] [Citation(s) in RCA: 76] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- H. Hampel
- AXA Research Fund & UPMC Chair, Paris, France
- Département de Neurologie, Sorbonne Universités, Université Pierre et Marie Curie (UPMC), Paris 06, Inserm, CNRS, Institut du cerveau et de la moelle (ICM), Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Boulevard de l'hôpital, Paris, France
| | - S. E. O’Bryant
- Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA
| | - S. Durrleman
- ARAMIS Lab, Inria Paris, Paris, France
- Sorbonne Universités, UPMC Univ Paris 06, Inserm, CNRS, Institut du cerveau et la moelle (ICM), Hôpital Pitié-Salpêtrière, Boulevard de l’hôpital, Paris, France
| | - E. Younesi
- European Society for Translational Medicine, Vienna, Austria
| | - K. Rojkova
- AXA Research Fund & UPMC Chair, Paris, France
- Département de Neurologie, Sorbonne Universités, Université Pierre et Marie Curie (UPMC), Paris 06, Inserm, CNRS, Institut du cerveau et de la moelle (ICM), Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Boulevard de l'hôpital, Paris, France
| | - V. Escott-Price
- Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK
| | - J-C. Corvol
- Département de Neurologie, Sorbonne Université, Université Pierre et Marie Curie, Paris 06 UMR S 1127, Institut National de Santé et en Recherche Médicale (INSERM) U 1127 and CIC-1422, Centre National de Recherche Scientifique U 7225, Institut du Cerveau et de la Moelle Epinière, Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France
| | - K. Broich
- President, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - B. Dubois
- Département de Neurologie, Sorbonne Universités, Université Pierre et Marie Curie (UPMC), Paris 06, Inserm, CNRS, Institut du cerveau et de la moelle (ICM), Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Boulevard de l'hôpital, Paris, France
| | - S. Lista
- AXA Research Fund & UPMC Chair, Paris, France
- Département de Neurologie, Sorbonne Universités, Université Pierre et Marie Curie (UPMC), Paris 06, Inserm, CNRS, Institut du cerveau et de la moelle (ICM), Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Boulevard de l'hôpital, Paris, France
| | | |
Collapse
|
32
|
Dubois B, Wilcox C, Weintraub J, Susman J, Sperling D, Sheynzon V, Schlossberg P, Chheang S, Reis S, Mobley D. Efficacy and safety of partial splenic embolization in patients with splenomegaly associated cytopenias. J Vasc Interv Radiol 2017. [DOI: 10.1016/j.jvir.2016.12.755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
33
|
Hampel H, O'Bryant SE, Castrillo JI, Ritchie C, Rojkova K, Broich K, Benda N, Nisticò R, Frank RA, Dubois B, Escott-Price V, Lista S. PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. J Prev Alzheimers Dis 2016; 3:243-259. [PMID: 28344933 PMCID: PMC5363725 DOI: 10.14283/jpad.2016.112] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
During this decade, breakthrough conceptual shifts have commenced to emerge in the field of Alzheimer's disease (AD) recognizing risk factors and the non-linear dynamic continuum of complex pathophysiologies amongst a wide dimensional spectrum of multi-factorial brain proteinopathies/neurodegenerative diseases. As is the case in most fields of medicine, substantial advancements in detecting, treating and preventing AD will likely evolve from the generation and implementation of a systematic precision medicine strategy. This approach will likely be based on the success found from more advanced research fields, such as oncology. Precision medicine will require integration and transfertilization across fragmented specialities of medicine and direct reintegration of Neuroscience, Neurology and Psychiatry into a continuum of medical sciences away from the silo approach. Precision medicine is biomarker-guided medicine on systems-levels that takes into account methodological advancements and discoveries of the comprehensive pathophysiological profiles of complex multi-factorial neurodegenerative diseases, such as late-onset sporadic AD. This will allow identifying and characterizing the disease processes at the asymptomatic preclinical stage, where pathophysiological and topographical abnormalities precede overt clinical symptoms by many years to decades. In this respect, the uncharted territory of the AD preclinical stage has become a major research challenge as the field postulates that early biomarker guided customized interventions may offer the best chance of therapeutic success. Clarification and practical operationalization is needed for comprehensive dissection and classification of interacting and converging disease mechanisms, description of genomic and epigenetic drivers, natural history trajectories through space and time, surrogate biomarkers and indicators of risk and progression, as well as considerations about the regulatory, ethical, political and societal consequences of early detection at asymptomatic stages. In this scenario, the integrated roles of genome sequencing, investigations of comprehensive fluid-based biomarkers and multimodal neuroimaging will be of key importance for the identification of distinct molecular mechanisms and signaling pathways in subsets of asymptomatic people at greatest risk for progression to clinical milestones due to those specific pathways. The precision medicine strategy facilitates a paradigm shift in Neuroscience and AD research and development away from the classical "one-size-fits-all" approach in drug discovery towards biomarker guided "molecularly" tailored therapy for truly effective treatment and prevention options. After the long and winding decade of failed therapy trials progress towards the holistic systems-based strategy of precision medicine may finally turn into the new age of scientific and medical success curbing the global AD epidemic.
Collapse
Affiliation(s)
- H Hampel
- AXA Research Fund & UPMC Chair, Paris, France; Sorbonne Universities, Pierre and Marie Curie University, Paris 06, Institute of Memory and Alzheimer's Disease (IM2A) & Brain and Spine Institute (ICM) UMR S 1127, Department of Neurology, Pitié-Salpêtrière University Hospital, Paris, France
| | - S E O'Bryant
- Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX USA
| | - J I Castrillo
- Genetadi Biotech S.L. Parque Tecnológico de Bizkaia, Derio, Bizkaia, Spain
| | - C Ritchie
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - K Rojkova
- AXA Research Fund & UPMC Chair, Paris, France; Sorbonne Universities, Pierre and Marie Curie University, Paris 06, Institute of Memory and Alzheimer's Disease (IM2A) & Brain and Spine Institute (ICM) UMR S 1127, Department of Neurology, Pitié-Salpêtrière University Hospital, Paris, France
| | - K Broich
- President, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - N Benda
- Biostatistics and Special Pharmacokinetics Unit/Research Division, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
| | - R Nisticò
- Department of Biology, University of Rome "Tor Vergata" & Pharmacology of Synaptic Disease Lab, European Brain Research Institute (E.B.R.I.), Rome, Italy
| | - R A Frank
- Siemens Healthineers North America, Siemens Medical Solutions USA, Inc, Malvern, PA, USA
| | - B Dubois
- AXA Research Fund & UPMC Chair, Paris, France; Sorbonne Universities, Pierre and Marie Curie University, Paris 06, Institute of Memory and Alzheimer's Disease (IM2A) & Brain and Spine Institute (ICM) UMR S 1127, Department of Neurology, Pitié-Salpêtrière University Hospital, Paris, France
| | - V Escott-Price
- Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, UK
| | - S Lista
- AXA Research Fund & UPMC Chair, Paris, France; IHU-A-ICM - Paris Institute of Translational Neurosciences, Pitié-Salpêtrière University Hospital, Paris, France
| |
Collapse
|
34
|
Dubois B, Bertin P, Mingeot D. Molecular diversity of α-gliadin expressed genes in genetically contrasted spelt ( Triticum aestivum ssp. spelta) accessions and comparison with bread wheat ( T. aestivum ssp. aestivum) and related diploid Triticum and Aegilops species. Mol Breed 2016; 36:152. [PMID: 27942245 PMCID: PMC5104789 DOI: 10.1007/s11032-016-0569-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Accepted: 10/11/2016] [Indexed: 05/31/2023]
Abstract
The gluten proteins of cereals such as bread wheat (Triticum aestivum ssp. aestivum) and spelt (T. aestivum ssp. spelta) are responsible for celiac disease (CD). The α-gliadins constitute the most immunogenic class of gluten proteins as they include four main T-cell stimulatory epitopes that affect CD patients. Spelt has been less studied than bread wheat and could constitute a source of valuable diversity. The objective of this work was to study the genetic diversity of spelt α-gliadin transcripts and to compare it with those of bread wheat. Genotyping data from 85 spelt accessions obtained with 19 simple sequence repeat (SSR) markers were used to select 11 contrasted accessions, from which 446 full open reading frame α-gliadin genes were cloned and sequenced, which revealed a high allelic diversity. High variations among the accessions were highlighted, in terms of the proportion of α-gliadin sequences from each of the three genomes (A, B and D), and their composition in the four T-cell stimulatory epitopes. An accession from Tajikistan stood out, having a particularly high proportion of α-gliadins from the B genome and a low immunogenic content. Even if no clear separation between spelt and bread wheat sequences was shown, spelt α-gliadins displayed specific features concerning e.g. the frequencies of some amino acid substitutions. Given this observation and the variations in toxicity revealed in the spelt accessions in this study, the high genetic diversity held in spelt germplasm collections could be a valuable resource in the development of safer varieties for CD patients.
Collapse
Affiliation(s)
- Benjamin Dubois
- Centre wallon de Recherches agronomiques (CRA-W), Département Sciences du vivant, Chaussée de Charleroi, 234, 5030 Gembloux, Belgium
- Earth and Life Institute – Agronomy, Université catholique de Louvain (UCL), Croix du Sud, 2 bte L7.05.11, 1348 Louvain-la-Neuve, Belgium
| | - Pierre Bertin
- Earth and Life Institute – Agronomy, Université catholique de Louvain (UCL), Croix du Sud, 2 bte L7.05.11, 1348 Louvain-la-Neuve, Belgium
| | - Dominique Mingeot
- Centre wallon de Recherches agronomiques (CRA-W), Département Sciences du vivant, Chaussée de Charleroi, 234, 5030 Gembloux, Belgium
| |
Collapse
|
35
|
Abstract
A partir d'une étude paneuropéenne portant sur 12 500 consommateurs et leurs attitudes vis-à-vis de 30 marques internationales, le présent article compare le pouvoir segmentant d'un ensemble d'indicateurs géographiques et socio-économiques susceptibles d'éclairer l'achat de marques de luxe. Bien que certaines différences entre les pays européens soient observées, les résultats obtenus révèlent que le revenu, le niveau d'éducation et la catégorie professionnelle différencient les consommateurs mieux que leur affiliation nationale. Dans cette mesure, on doit conclure à l'existence d'un euroconsommateur du luxe dont le portrait robot peut être dressé avec une relative précision
Collapse
|
36
|
Dujardin K, Auzou N, Lhommée E, Czernecki V, Dubois B, Fradet A, Maltete D, Meyer M, Pineau F, Schmitt E, Sellal F, Tison F, Vidal T, Azulay JP, Welter ML, Corvol JC, Durif F, Rascol O. French consensus procedure for assessing cognitive function in Parkinson's disease. Rev Neurol (Paris) 2016; 172:696-702. [PMID: 27318613 DOI: 10.1016/j.neurol.2016.05.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Accepted: 05/25/2016] [Indexed: 12/11/2022]
Abstract
INTRODUCTION One of the objectives of the French expert centers for Parkinson's disease (NS-Park) network was to determine a consensus procedure for assessing cognitive function in patients with Parkinson's. This article presents this procedure and briefly describes the selected tests. METHODS A group of 13 experts used the Delphi method for consensus building to define the overall structure and components of the assessment procedure. For inclusion in the battery, tests had to be validated in the French language, require little motor participation, have normative data and be recognized by the international community. Experimental tasks and tests requiring specific devices were excluded. RESULTS Two possibilities were identified, depending on whether an abbreviated or comprehensive assessment of cognitive function was necessary. For an abbreviated assessment, the experts recommended the Montreal Cognitive Assessment (MoCA) as a screening test for cognitive impairment or dementia. For a comprehensive neuropsychological assessment, the experts recommended assessing global efficiency plus the five main cognitive domains (attention and working memory, executive function, episodic memory, visuospatial function and language) that may be impaired in Parkinson's disease, using two tests for each domain. DISCUSSION AND CONCLUSION A common procedure for assessing cognitive function is now available across the French network dedicated to Parkinson's disease, and is recommended for both research and clinical practice. It will also help to promote standardization of the neuropsychological assessment of Parkinson's disease.
Collapse
Affiliation(s)
- K Dujardin
- Université de Lille, Inserm U1171, Degenerative & Vascular Cognitive Disorders, 59000 Lille, France; CHU de Lille, Neurology and Movement Disorders, 59000 Lille, France.
| | - N Auzou
- Institute of Neurodegenerative Disorders, CHU de Bordeaux, 33000 Bordeaux, France; Université de Bordeaux, Psychology Laboratory, EA4139, 33000 Bordeaux, France
| | - E Lhommée
- CHU de Grenoble Alpes, Inserm U1216, 38000 Grenoble, France; Université Grenoble Alpes, Grenoble Institut des Neurosciences (GIN), 38000 Grenoble, France
| | - V Czernecki
- CRICM UMRS 975, Neurology Department, AP-HP, Salpetrière Hospital, 75013 Paris, France
| | - B Dubois
- Université Pierre-et-Marie-Curie, Paris VI, ICM, Inserm UMR_S975, Dementia Research Center (IM2A), Salpêtrière Hospital, 75013 Paris, France
| | - A Fradet
- CHU de Poitiers, Neurology & Neuropsychology, Expert Referent Center of Parkinson Disease, CMRR, 86000 Poitiers, France
| | - D Maltete
- Department of Neurology, Rouen University Hospital, 76031 Rouen, France; Inserm U1073, Rouen Faculty of Medicine, 76031 Rouen, France
| | - M Meyer
- CHU de Nancy, Department of Neurology, 54000 Nancy, France
| | - F Pineau
- Département de Neurologie, Hôpitaux Civils de Colmar, 68000 Colmar, France
| | - E Schmitt
- Université Pierre-et-Marie-Curie, Paris VI, ICM, Inserm UMR_S975, Dementia Research Center (IM2A), Salpêtrière Hospital, 75013 Paris, France; CHU de Poitiers, Neurology & Neuropsychology, Expert Referent Center of Parkinson Disease, CMRR, 86000 Poitiers, France
| | - F Sellal
- Département de Neurologie, Hôpitaux Civils de Colmar, 68000 Colmar, France; Inserm U1118, Université de Strasbourg, 67085 Strasbourg, France
| | - F Tison
- Institute of Neurodegenerative Disorders, CHU de Bordeaux, 33000 Bordeaux, France
| | - T Vidal
- CHU de Clermont-Ferrand, Movement Disorders Centre, 63000 Clermont-Ferrand, France; CHU de Clermont-Ferrand, Resource and Research Memory Centre, 63000 Clermont-Ferrand, France
| | - J-P Azulay
- Neurology and Movement Disorders, Hôpital de la Timone, AP-HM, Institut des Neurosciences de la Timone, Université Aix-Marseille, 13385 Marseille, France
| | | | - J-C Corvol
- Sorbonne Universités, UPMC Université Paris 06, Inserm UMRS-1127, CIC-1422, CNRS UMR-7225, AP-HP, ICM, Hôpital Pitié-Salpêtrière, Département des Maladies du Système Nerveux, 75013 Paris, France
| | - F Durif
- CHU de Clermont-Ferrand, Movement Disorders Centre, 63000 Clermont-Ferrand, France
| | - O Rascol
- Clinical Investigation Center (CIC) 1436, Department of Clinical Pharmacolgy and Neurosciences, Inserm, Toulouse University Hospital, University of Toulouse, 31059 Toulouse, France
| | | |
Collapse
|
37
|
Dubois B, Fontaine M, Rorive G, Dwelshauvcrs J, Krzesinski J, Rorive G. Abstracts of the meeting of the Belgian Society of Internal Medicine (7 May 1994). Acta Clin Belg 2016. [DOI: 10.1080/17843286.1994.11718387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Scherrer B, Andrieu S, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Vellas B. Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761. J Nutr Health Aging 2015; 19:1009-11. [PMID: 26624212 DOI: 10.1007/s12603-015-0661-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Time-to-event analysis is frequently used in medical research to investigate potential disease-modifying treatments in neurodegenerative diseases. Potential treatment effects are generally evaluated using the logrank test, which has optimal power and sensitivity when the treatment effect (hazard ratio) is constant over time. However, there is generally no prior information as to how the hazard ratio for the event of interest actually evolves. In these cases, the logrank test is not necessarily the most appropriate to use. When the hazard ratio is expected to decrease or increase over time, alternative statistical tests such as the Fleming-Harrington test, provide a better sensitivity. An example of this comes from a large, five-year randomised, placebo-controlled prevention trial (GuidAge) in 2854 community-based subjects making spontaneous memory complaints to their family physicians, which evaluated whether treatment with EGb761 can modify the risk of developing AD. The primary outcome measure was the time to conversion from memory complaint to Alzheimer's type dementia. Although there was no significant difference in the hazard function of conversion between the two treatment groups according to the preplanned logrank test, a significant treatment-by-time interaction for the incidence of AD was observed in a protocol-specified subgroup analysis, suggesting that the hazard ratio is not constant over time. For this reason, additional post hoc analyses were performed using the Fleming-Harrington test to evaluate whether there was a signal of a late effect of EGb761. Applying the Fleming-Harrington test, the hazard function for conversion to dementia in the placebo group was significantly different from that in the EGb761 treatment group (p = 0.0054), suggesting a late effect of EGb761. Since this was a post hoc analysis, no definitive conclusions can be drawn as to the effectiveness of the treatment. This post hoc analysis illustrates the interest of performing another randomised clinical trial of EGb761 explicitly testing the hypothesis of a late treatment effect, as well as of using of better adapted statistical approaches for long term preventive trials when it is expected that prevention cannot have an immediate effect but rather a delayed effect that increases over time.
Collapse
Affiliation(s)
- B Scherrer
- Bruno Scherrer, 15 rue Beethoven, 78730 Saint Arnoult en Yvelines, France, Tel.: +33 1 30 59 31 85;
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Drevelle X, Demain A, Collomb-Clerc A, Trinkler I, Fernandez-Vidal S, Dürr A, Dubois B, Welter ML. Rôle des ganglions de la base dans la coordination entre les ajustements posturaux et l’exécution du pas chez l’homme. Neurophysiol Clin 2015. [DOI: 10.1016/j.neucli.2015.10.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
40
|
Corlier F, Rivals I, Lagarde J, Hamelin L, Corne H, Dauphinot L, Ando K, Cossec JC, Fontaine G, Dorothée G, Malaplate-Armand C, Olivier JL, Dubois B, Bottlaender M, Duyckaerts C, Sarazin M, Potier MC. Modifications of the endosomal compartment in peripheral blood mononuclear cells and fibroblasts from Alzheimer's disease patients. Transl Psychiatry 2015; 5:e595. [PMID: 26151923 PMCID: PMC5068716 DOI: 10.1038/tp.2015.87] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Accepted: 05/21/2015] [Indexed: 12/16/2022] Open
Abstract
Identification of blood-based biomarkers of Alzheimer's disease (AD) remains a challenge. Neuropathological studies have identified enlarged endosomes in post-mortem brains as the earliest cellular change associated to AD. Here the presence of enlarged endosomes was investigated in peripheral blood mononuclear cells from 48 biologically defined AD patients (25 with mild cognitive impairment and 23 with dementia (AD-D)), and 23 age-matched healthy controls using immunocytochemistry and confocal microscopy. The volume and number of endosomes were not significantly different between AD and controls. However, the percentage of cells containing enlarged endosomes was significantly higher in the AD-D group as compared with controls. Furthermore, endosomal volumes significantly correlated to [C(11)]PiB cortical index measured by positron emission tomography in the AD group, independently of the APOE genotype, but not to the levels of amyloid-beta, tau and phosphorylated tau measured in the cerebrospinal fluid. Importantly, we confirmed the presence of enlarged endosomes in fibroblasts from six unrelated AD-D patients as compared with five cognitively normal controls. This study is the first, to our knowledge, to report morphological alterations of the endosomal compartment in peripheral cells from AD patients correlated to amyloid load that will now be evaluated as a possible biomarker.
Collapse
Affiliation(s)
- F Corlier
- UPMC University Paris 06, UMRS 1127, Sorbonne Universités, Paris, France,INSERM U 1127, Paris, France,ICM Research Centre, CNRS UMR 7225, Paris, France
| | - I Rivals
- Équipe de Statistique Appliquée, ESPCI ParisTech, PSL Research University, INSERM UMRS 1158, Paris, France
| | - J Lagarde
- Neurologie de la Mémoire et du Langage, Service de Neurologie, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France
| | - L Hamelin
- Neurologie de la Mémoire et du Langage, Service de Neurologie, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France
| | - H Corne
- Neurologie de la Mémoire et du Langage, Service de Neurologie, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France
| | - L Dauphinot
- UPMC University Paris 06, UMRS 1127, Sorbonne Universités, Paris, France,INSERM U 1127, Paris, France,ICM Research Centre, CNRS UMR 7225, Paris, France
| | - K Ando
- UPMC University Paris 06, UMRS 1127, Sorbonne Universités, Paris, France,INSERM U 1127, Paris, France,ICM Research Centre, CNRS UMR 7225, Paris, France
| | - J-C Cossec
- UPMC University Paris 06, UMRS 1127, Sorbonne Universités, Paris, France,INSERM U 1127, Paris, France,ICM Research Centre, CNRS UMR 7225, Paris, France
| | - G Fontaine
- UPMC University Paris 06, UMRS 1127, Sorbonne Universités, Paris, France,INSERM U 1127, Paris, France,ICM Research Centre, CNRS UMR 7225, Paris, France
| | - G Dorothée
- INSERM UMRS 938, Laboratoire Système Immunitaire et Maladies Conformationnelles, Hôpital Saint-Antoine, Paris, France,Université Pierre et Marie Curie, Université Paris 6, Centre de Recherche Saint-Antoine, Hôpital Saint-Antoine, Paris, France
| | - C Malaplate-Armand
- Laboratoire de Biochimie et Biologie Moléculaire, UF Oncologie—Endocrinologie—Neurobiologie, Hôpital Central, Centre Hospitalier Universitaire, Nancy, France,UR AFPA—USC 340, Equipe BFLA, Université de Lorraine, Nancy, France
| | - J-L Olivier
- Laboratoire de Biochimie et Biologie Moléculaire, UF Oncologie—Endocrinologie—Neurobiologie, Hôpital Central, Centre Hospitalier Universitaire, Nancy, France,UR AFPA—USC 340, Equipe BFLA, Université de Lorraine, Nancy, France
| | - B Dubois
- Institut de la mémoire et de la maladie d'Alzheimer, IMMA, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France
| | - M Bottlaender
- CEA (MB), DSV, Institut d'Imagerie Biomédicale, Service Hospitalier Frédéric Joliot, Orsay, France
| | - C Duyckaerts
- UPMC University Paris 06, UMRS 1127, Sorbonne Universités, Paris, France,INSERM U 1127, Paris, France,ICM Research Centre, CNRS UMR 7225, Paris, France,Laboratoire de Neuropathologie Escourolle, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France
| | - M Sarazin
- Neurologie de la Mémoire et du Langage, Service de Neurologie, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France
| | - M-C Potier
- UPMC University Paris 06, UMRS 1127, Sorbonne Universités, Paris, France,INSERM U 1127, Paris, France,ICM Research Centre, CNRS UMR 7225, Paris, France,ICM Research Centre, Group of Alzheimer's and Prion's diseases, CNRS UMR7225, INSERM URM975, UPMC, Hôpital de la Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, 75013 Paris, France. E-mail:
| | | |
Collapse
|
41
|
|
42
|
Gauthier S, Dubois B, Poirier J, Leuzy A, Rosa-Neto P. Le diagnostic précoce de la maladie d’Alzheimer : panacée ou catastrophe ? ACTA ACUST UNITED AC 2015. [DOI: 10.1016/j.jemep.2015.04.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
43
|
Huart J, Dubois B, Krzesinski JM, Jouret F. [Management of hypophosphatemia: a case report]. Rev Med Liege 2015; 70:163-168. [PMID: 26054165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Hypophosphatemia is defined by a serum phosphate level lower than 0.8 mmol/l. If hypophosphatemia is chronically maintained, it is associated with muscular, osteous, neurological or cardio-respiratory disorders. We describe a patient with isolated hypophosphatemia, detail the mechanisms of phosphate homeostasis, and envisage the differential diagnosis of hypophosphatemia. Furthermore, we propose a sequential decisional algorithm based on basic biological tests and few complementary investigations. Treatment options are reviewed.
Collapse
|
44
|
Abstract
Alzheimer's disease (AD) represents an increasing worldwide healthcare epidemic. Secondary preventive disease-modifying treatments under clinical development are considered most effective when initiated as early as possible in the pathophysiological course and progression of the disease. Major targets are to enhance clearance and to reduce cerebral accumulation of amyloid, decrease hyperphosphorylation of tau and the generation of neurofibrillary tangles, reduce inflammation, and finally progressive neurodegeneration. Comprehensive sets of biological markers are needed to characterize the pathophysiological mechanisms, indicate effects of treatment and to facilitate early characterisation and detection of AD during the prodromal or even at asymptomatic stages. No primary or secondary preventive treatments for AD have been approved. Epidemiological research, however, has provided evidence of specifically modifiable risk and protective factors. Among them are vascular, lifestyle and psychological risk factors that may act both independently and by potentiating each other. These factors may be substantially impacted by single or multi-domain strategies to prevent or postpone the onset of AD-related pathophysiology. Researchers have recently started the European Dementia Prevention Initiative (EDPI), an international consortium to improve strategies for preventing dementia. EDPI, in particular, includes the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) which aims at optimizing the early identification of subjects at increased risk of late-life cognitive deterioration, and at the evaluation of multi-domain intervention strategies. The ongoing discussion on new diagnostic criteria provided by the International Working Group (IWG), as well as by the recommendations summoned by the National Institute on Aging and Alzheimer's Association (NIA-AA) initiative, has inspired the creation of novel study designs and the definition of earlier target populations for trials in pre- and asymptomatic at-risk and prodromal stages of AD. As a result, a number of promising international prevention trials are currently ongoing. In this review, we critically discuss the main paths to AD prevention through control of modifiable risk factors and lifestyle changes. We will also review the role of biomarkers to identify subgroups of patients who would most likely benefit from secondary prevention strategies, and to evaluate the benefit of treatment in such patients.
Collapse
Affiliation(s)
- S Lista
- S. Lista, Sorbonne Universités, Université Pierre et Marie Curie, Paris 06, Institut de la Mémoire et de la Maladie d'Alzheimer (IM2A) and Institut du Cerveau et de la Moelle épinière (ICM), Département de Neurologie, Hôpital de la Pitié-Salpétrière, Paris, France,
| | | | | |
Collapse
|
45
|
Bertoux M, Volle E, de Souza LC, Funkiewiez A, Dubois B, Habert MO. Neural correlates of the mini-SEA (Social cognition and Emotional Assessment) in behavioral variant frontotemporal dementia. Brain Imaging Behav 2014; 8:1-6. [PMID: 24078043 DOI: 10.1007/s11682-013-9261-0] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Although Frontotemporal Dementia (FTD) is the second most common form of dementia after Alzheimer’s disease, its diagnosis remains particularly challenging today. This is particularly true for the behavioral variant (bvFTD), the most common phenotype of FTD, which is characterised by dramatic changes in personal and social conduct. Novel clinical cognitive tests have been recently proposed to diagnose and assess these patients. Among them, the mini-SEA (Social cognition & Emotional Assessment) has shown promising results. This quick clinical tool evaluates emotion recognition and theory of mind deficits, both recognized as hallmark features of bvFTD. In this study, we investigated the neural correlates of the mini-SEA in twenty bvFTD patients, using single photon emission computed tomography (SPECT) and focusing on the mPFC. Results showed that detection of faux pas during a theory of mind evaluation was related to rostral mPFC perfusion (BA 10) while recognition of emotion involved more dorsal regions within the mPFC (BA 9). As significant and early dysfunction of the mPFC has been extensively described in bvFTD, this study supports the use of the mini-SEA in evaluation and diagnosis purposes in bvFTD.
Collapse
|
46
|
Gadisseur R, Castiglione V, Jouret F, Bruyère O, Bekaert A, Thomas A, Dubois B, Waltrégny D, Cavalier E. Épidémiologie de la lithiase urinaire en Province de Liège. Nephrol Ther 2014. [DOI: 10.1016/j.nephro.2014.07.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
47
|
Cavalier E, Dubois B, Bekaert AC, Lukas P, Peeters S, Gadisseur R, Le Goff C, Krzesinski JM, Delanaye P. La membrane de dialyse peut-elle avoir un impact sur le statut vitaminique D du patient ? Nephrol Ther 2014. [DOI: 10.1016/j.nephro.2014.07.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
48
|
Janel N, Sarazin M, Corlier F, Corne H, de Souza LC, Hamelin L, Aka A, Lagarde J, Blehaut H, Hindié V, Rain JC, Arbones ML, Dubois B, Potier MC, Bottlaender M, Delabar JM. Plasma DYRK1A as a novel risk factor for Alzheimer's disease. Transl Psychiatry 2014; 4:e425. [PMID: 25116835 PMCID: PMC4150238 DOI: 10.1038/tp.2014.61] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Accepted: 06/05/2014] [Indexed: 12/23/2022] Open
Abstract
To determine whether apparent involvement of DYRK1A in Alzheimer's disease (AD) pathology makes it a candidate plasma biomarker for diagnosis, we developed a method to quantify plasma DYRK1A by immunoblot in transgenic mouse models having different gene dosages of Dyrk1a, and, consequently, different relative protein expression. Then, we measured plasma DYRK1A levels in 26 patients with biologically confirmed AD and 25 controls (negative amyloid imaging available on 13). DYRK1A was detected in transgenic mouse brain and plasma samples, and relative levels of DYRK1A correlated with the gene copy number. In plasma from AD patients, DYRK1A levels were significantly lower compared with controls (P<0.0001). Results were similar when we compared AD patients with the subgroup of controls confirmed by negative amyloid imaging. In a subgroup of patients with early AD (CDR=0.5), lower DYRK1A expression was confirmed. In contrast, no difference was found in levels of DYRK1B, the closest relative of DYRK1A, between AD patients and controls. Further, AD patients exhibited a positive correlation between plasma DYRK1A levels and cerebrospinal fluid tau and phosphorylated-tau proteins, but no correlation with amyloid-β42 levels and Pittsburgh compound B cortical binding. DYRK1A levels detected in lymphoblastoid cell lines from AD patients were also lower when compared with cells from age-matched controls. These findings suggest that reduced DYRK1A expression might be a novel plasma risk factor for AD.
Collapse
Affiliation(s)
- N Janel
- Unité de Biologie Fonctionnelle et Adaptative, Sorbonne Paris Cité, Université Paris Diderot, EAC4413 CNRS, Paris, France
| | - M Sarazin
- Department of Neurology, Neurology of Memory and Langage, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France
| | - F Corlier
- Department of Neurology, Alzheimer Institute (MB, LCdS, BD, MS), Hôpital Pitié-Salpêtrière (Assistance Publique—Hôpitaux de Paris), Paris, France
- Brain & Spine Institute (ICM) CNRS UMR7225, INSERM UMRS 975, Paris, France
- Université Pierre et Marie Curie, Sorbonne Universités, Paris, France
| | - H Corne
- Department of Neurology, Alzheimer Institute (MB, LCdS, BD, MS), Hôpital Pitié-Salpêtrière (Assistance Publique—Hôpitaux de Paris), Paris, France
- Brain & Spine Institute (ICM) CNRS UMR7225, INSERM UMRS 975, Paris, France
| | - L C de Souza
- Department of Neurology, Alzheimer Institute (MB, LCdS, BD, MS), Hôpital Pitié-Salpêtrière (Assistance Publique—Hôpitaux de Paris), Paris, France
- Brain & Spine Institute (ICM) CNRS UMR7225, INSERM UMRS 975, Paris, France
- Université Pierre et Marie Curie, Sorbonne Universités, Paris, France
| | - L Hamelin
- Department of Neurology, Neurology of Memory and Langage, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France
| | - A Aka
- Unité de Biologie Fonctionnelle et Adaptative, Sorbonne Paris Cité, Université Paris Diderot, EAC4413 CNRS, Paris, France
| | - J Lagarde
- Department of Neurology, Neurology of Memory and Langage, Université Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France
| | - H Blehaut
- Fondation Jérome Lejeune, Paris, France
| | - V Hindié
- HYBRIGENICS Services SAS, Paris, France
| | - J-C Rain
- HYBRIGENICS Services SAS, Paris, France
| | - M L Arbones
- Instituto de Biología Molecular de Barcelona (CSIC), Barcelona, Spain
| | - B Dubois
- Department of Neurology, Alzheimer Institute (MB, LCdS, BD, MS), Hôpital Pitié-Salpêtrière (Assistance Publique—Hôpitaux de Paris), Paris, France
- Brain & Spine Institute (ICM) CNRS UMR7225, INSERM UMRS 975, Paris, France
| | - M C Potier
- Brain & Spine Institute (ICM) CNRS UMR7225, INSERM UMRS 975, Paris, France
| | - M Bottlaender
- CEA (MB), DSV, Institut d'Imagerie Biomédicale, Service Hospitalier Frédéric Joliot, Orsay, France
| | - J M Delabar
- Unité de Biologie Fonctionnelle et Adaptative, Sorbonne Paris Cité, Université Paris Diderot, EAC4413 CNRS, Paris, France
| |
Collapse
|
49
|
Morris JC, Blennow K, Froelich L, Nordberg A, Soininen H, Waldemar G, Wahlund LO, Dubois B. Harmonized diagnostic criteria for Alzheimer's disease: recommendations. J Intern Med 2014; 275:204-13. [PMID: 24605805 DOI: 10.1111/joim.12199] [Citation(s) in RCA: 88] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Two major sets of criteria for the clinical diagnosis of Alzheimer's disease (AD) recently have been published, one from an International Working Group (IWG) and the other from working groups convened by the National Institute on Aging (NIA) and the Alzheimer's Association (AA) in the United States. These criteria both aim to support a clinical diagnosis with in vivo evidence of AD pathology, using imaging methods and detection of biofluid biomarkers, and emphasize an aetiological diagnosis even in the prodromal stages of the disorder. Nonetheless, there are substantial differences in these two sets of criteria. METHODS An international group of investigators with experience in the clinical diagnosis of AD met at the Key Symposium in Stockholm, Sweden on 6 & 7 December 2012, to develop recommendations to harmonize these criteria. The group was led by individuals who were integral to the development of both the IWG and the NIA-AA criteria. The similarities and differences between the two sets of criteria were identified and open discussion focused on ways to resolve the differences and thus yield a harmonized set of criteria. RESULTS Based on both published evidence as well as the group's collective clinical experience, the group was tasked with achieving consensus, if not unanimity, as it developed recommendations for harmonized clinical diagnostic criteria for AD. CONCLUSION The recommendations are to: (i) define AD as a brain disorder, regardless of clinical status; (ii) refer to the clinically expressed disorder, including its prodromal stages, as symptomatic AD; (iii) after the successful completion of standardization efforts, consider incorporating biomarkers into diagnostic algorithms for AD; and (iv) allow nonamnestic, atypical presentations to be included as symptomatic AD, especially when there is supportive biomarker evidence.
Collapse
Affiliation(s)
- J C Morris
- Department of Neurology, Washington University, St. Louis, MO, USA
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Gauthier S, Johnson K, Dubois B. Communicating the diagnosis of Alzheimer's disease: Dilemmas and perspectives. Neurobiol Aging 2014. [DOI: 10.1016/j.neurobiolaging.2014.01.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|